Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Iproniazid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.96 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.96 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.96 |
| ▸ | HPGD | P15428 | 3/20 | 0.87 |
| ▸ | LMNA | P02545 | 2/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 4/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MPO | P05164 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iproniazid SCHEMBL3001881 | 1.00 | MAOA (0.96) | MAOAMAOBPTGS2HPGDLMNA | |
| Iproniazid SCHEMBL4153 | 0.98 | MAOA (1.00) | MAOAMAOBPTGS2HPGDLMNA | |
| Iproniazid SCHEMBL158555 | 0.93 | HPGD (1.00) | MAOAMAOBPTGS2HPGDLMNA | |
| Iproniazid SCHEMBL15200763 | 0.91 | HPGD (1.00) | MAOAMAOBPTGS2HPGDLMNA | |
| SCHEMBL3001440 | 0.81 | MAOA (0.70) | MAOAMAOBPTGS2HPGDLMNA | |
| SCHEMBL3363035 | 0.81 | MAOA (0.70) | MAOAMAOBPTGS2HPGDLMNA | |
| SCHEMBL2999066 | 0.80 | MAOA (0.68) | MAOAMAOBPTGS2HPGDLMNA | |
| SCHEMBL2992964 | 0.80 | ALDH1A1 (1.00) | MAOAMAOBPTGS2HPGDLMNA | |
| SCHEMBL2989617 | 0.79 | MAOA (0.67) | MAOAMAOBPTGS2HPGDLMNA | |
| SCHEMBL5394237 | 0.79 | PTGS2 (0.67) | MAOAMAOBPTGS2HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103788094-A | Preparation method of ketone drug intermediate | WUXI VISION PRO LTD | 2014-05-14 | — | — | CN | claimed |
| EP-2118048-B1 | MALE CONTRACEPTIVE | AMOBI NNAEMEKA IKECHUKWU (GB) | 2016-11-23 | — | — | EP | disclosed |
| CN-102977095-B | Pyrazolo quinolines and uses thereof | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2015-10-28 | — | — | CN | disclosed |
| CN-104918934-A | 3-substituted pyrazoles and their use as DLK inhibitors | HOFFMANN LA ROCHE | 2015-09-16 | — | — | CN | disclosed |
| CN-104774205-A | N1/N2-lactam acetyl-coa carboxylase inhibitors | PFIZER | 2015-07-15 | — | — | CN | disclosed |
| CN-103189377-B | N1/n2-lactam acetyl-coa carboxylase inhibitors | PFIZER | 2015-02-25 | — | — | CN | disclosed |
| US-8927579-B2 | Male contraceptive | Amobi, Nnaemkea Ikechukwu (GB) | 2015-01-06 | — | — | US | disclosed |
| CN-102695708-B | N1-pyrazolospiroketone acetyl-coA carboxylase inhibitors | PFIZER INC. (US) | 2014-10-15 | — | — | CN | disclosed |
| US-8778968-B2 | — | — | 2014-07-15 | — | — | US | disclosed |
| CN-103788093-A | Ketone drug intermediate | WUXI VISION PRO LTD | 2014-05-14 | — | — | CN | disclosed |
| CN-103788094-A | Preparation method of ketone drug intermediate | WUXI VISION PRO LTD | 2014-05-14 | — | — | CN | disclosed |
| CN-103189377-A | N1/n2-lactam acetyl-coa carboxylase inhibitors | PFIZER | 2013-07-03 | — | — | CN | disclosed |
| CN-102977095-A | Pyrroloquinolines compound and application thereof | UNIV EAST CHINA SCIENCE & TECH | 2013-03-20 | — | — | CN | disclosed |
| CN-102695708-A | N1-pyrazolospiroketone acetyl-coA carboxylase inhibitors | PFIZER | 2012-09-26 | — | — | CN | disclosed |
| CN-101687809-A | Transition metal catalyzed synthesis of 2H-indazoles | SANOFI AVENTIS | 2010-03-31 | — | — | CN | disclosed |
| US-20100029624-A1 | Male Contraceptive | KING'S COLLEGE LONDON (GB) | 2010-02-04 | — | — | US | disclosed |
| EP-2118048-A2 | MALE CONTRACEPTIVE | King's College London (GB) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008087421-A2 | MALE CONTRACEPTIVE | KING'S COLLEGE LONDON (GB) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029624-A1 | Male Contraceptive | NR5A1, AR, CYP19A1 | MAOA 1119/4885MAOB 880/4885PTGS2 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.